Sugi Predict

Sugi Predict / Compounds / Isovaleramide

Isovaleramide

Isovaleramide

SCHEMBL5486726

CC(C)CC(N)=O.O=C(O)C(F)(F)F

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ CA2 P00918 1/20 0.36
▸ ECE1 P42892 3/20 0.34
▸ NOS1 P29475 1/20 0.34
▸ NOS2 P35228 1/20 0.34
▸ CACNA2D1 P54289 2/20 0.33
▸ CACNB3 P54284 1/20 0.33
▸ CACNA1C Q13936 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ PGR P06401 1/20 0.33
▸ ADRA1A P35348 1/20 0.33
▸ HTR2B P41595 1/20 0.33
▸ CACNA2D2 Q9NY47 1/20 0.33
▸ SLC7A5 Q01650 1/20 0.33
▸ DPP8 Q6V1X1 3/20 0.33
▸ DPP7 Q9UHL4 2/20 0.33
▸ DPP4 P27487 1/20 0.33
▸ MMP1 P03956 1/20 0.32
▸ MMP2 P08253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isovaleramide SCHEMBL6055503 0.83 ALDH1A1 (0.53) ALDH1A1TDP1CA2ECE1CACNA2D1
Isovaleramide SCHEMBL9641 0.83 — —
Isovaleramide SCHEMBL28439595 0.80 ALDH1A1 (0.52) ALDH1A1TDP1CA2ECE1CACNA2D1
Isovaleramide SCHEMBL28192598 0.80 ALDH1A1 (0.46) ALDH1A1TDP1CA2ECE1CACNA2D1
Isovaleramide SCHEMBL9271798 0.80 ALDH1A1 (0.46) ALDH1A1TDP1CA2ECE1CACNA2D1
Isovaleramide SCHEMBL28163028 0.80 — —
Isovaleramide SCHEMBL9846971 0.80 — —
Isovaleramide SCHEMBL7081542 0.80 — —
Isovaleramide SCHEMBL1650316 0.80 — —
Trifluoroacetic Acid SCHEMBL30164390 0.78 BLM (0.43) NOS1NOS2DPP8DPP7DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042740-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-12 — — US disclosed
US-20260027226-A1 ANTIBODY-DRUG CONJUGATES PHEON THERAPEUTICS LTD (GB) 2026-01-29 — — US disclosed
WO-2025149667-A1 ANTIBODY DRUG CONJUGATES AND USES THEREOF PHEON THERAPEUTICS LTD (GB) 2025-07-17 — — WO disclosed
EP-4554624-A1 ANTIBODY-DRUG CONJUGATES Pheon Therapeutics Ltd (GB) 2025-05-21 — — EP disclosed
CN-119836305-A Antibody-drug conjugates 费恩治疗有限公司 2025-04-15 — — CN disclosed
CN-119836306-A Antibody drug conjugates that bind CDCP1 and uses thereof 费恩治疗有限公司 2025-04-15 — — CN disclosed
US-11952352-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2024-04-09 — — US disclosed
WO-2024013724-A1 ANTIBODY-DRUG CONJUGATES PHEON THERAPEUTICS LTD (GB) 2024-01-18 — — WO disclosed
US-20230234929-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-07-27 — — US disclosed
EP-4208261-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. (US) 2023-07-12 — — EP disclosed
US-20180179203-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-06-28 — — US disclosed
CN-107674073-A 3,5 2 as protein kinase modulators substitute 3H imidazoles (or [1,2,3] triazole) simultaneously [4,5 B] pyridine compounds 印蔻真治疗公司 2018-02-09 — — CN disclosed
CN-103068824-B Novel 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridines and 3, 5-disubstituted-3H- [1,2,3] triazolo [4,5-B ] pyridine compounds as protein kinase modulators 印蔻真治疗公司 2017-09-08 — — CN disclosed
CN-106660954-A Substituted azaspiro(4.5)decane derivatives 格吕伦塔尔有限公司 2017-05-10 — — CN disclosed
CN-102753538-B Sultam derivatives HOFFMANN LA ROCHE 2015-04-08 — — CN disclosed
US-7309701-B2 Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-12-18 — — US disclosed
US-7217724-B2 Indole, indazole, and benzazole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2007-05-15 — — US disclosed
US-20060063762-A1 Indole indazole and benzazole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2006-03-23 — — US disclosed
EP-1514869-A1 INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-03-16 — — EP disclosed
EP-0190891-A2 Novel amino acid derivatives Kissei Pharmaceutical Co. Ltd. (JP) 1986-08-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042740-A1 RAS INHIBITORS KRAS, NRAS, HRAS ALDH1A1 4551/4885TDP1 4090/4885CA2 1899/4885
US-20060063762-A1 Indole indazole and benzazole derivative ADRB3, ADRA2C, ADRB2 ALDH1A1 847/4885TDP1 4618/4885CA2 2240/4885
US-20230234929-A1 RAS INHIBITORS KRAS, NRAS, HRAS ALDH1A1 4437/4885TDP1 3475/4885CA2 3819/4885
US-20180179203-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF ALDH1A1 2706/4885TDP1 755/4885CA2 2652/4885
US-20260027226-A1 ANTIBODY-DRUG CONJUGATES SLC3A2, MTCL3, SLC13A2 ALDH1A1 1177/4885TDP1 2123/4885CA2 615/4885
US-11952352-B2 Ras inhibitors KRAS, NRAS, HRAS ALDH1A1 4437/4885TDP1 3475/4885CA2 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.